Case of Fibrolamellar Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
Author Information
Author(s): Satoru Hagiwara, Itsuki Oda, Kazuomi Ueshima, Yoriaki Komeda, Naoshi Nishida, Akihiro Yoshida, Tomoki Yamamoto, Naoya Omaru, Takuya Matsubara, Masatoshi Kudo
Primary Institution: Kindai University Faculty of Medicine, Osaka, Japan
Hypothesis
Can combination therapy of atezolizumab and bevacizumab followed by radiation therapy effectively treat fibrolamellar hepatocellular carcinoma?
Conclusion
Combination therapy with atezolizumab, bevacizumab, and radiation therapy may be an option for the treatment of fibrolamellar hepatocellular carcinoma.
Supporting Evidence
- The patient was diagnosed with fibrolamellar hepatocellular carcinoma based on imaging and biopsy results.
- Combination therapy was resumed after radiation therapy to control the tumor.
- Previous treatments had failed, indicating the need for a new approach.
Takeaway
A 15-year-old girl with a rare liver cancer was treated with a mix of medicines and radiation, and it helped control her tumor.
Methodology
The patient received a combination of atezolizumab and bevacizumab followed by radiation therapy to control the tumor.
Limitations
The study is based on a single case report, limiting the generalizability of the findings.
Participant Demographics
The patient was a 15-year-old female with no notable medical history.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website